Celldex Therapeutics Presents 52-Week Results From Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria At EADV 2024; 71% Of Patients Achieved Complete Response At Week 52; Rapid, Profound And Durable Improvement In UAS7 As Early As Week 1 With A Deepening Of Response Over 52 Weeks
Portfolio Pulse from Benzinga Newsdesk
Celldex Therapeutics presented positive 52-week results from its Phase 2 study of barzolvolimab for chronic spontaneous urticaria, showing 71% of patients achieved complete response. The treatment demonstrated rapid and durable improvement, was well tolerated, and is moving to Phase 3 trials.
September 25, 2024 | 2:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Celldex Therapeutics' barzolvolimab showed promising results in a Phase 2 study for chronic spontaneous urticaria, with 71% of patients achieving complete response at 52 weeks. The drug was well tolerated and is advancing to Phase 3 trials.
The positive results from the Phase 2 study, including a high complete response rate and good tolerability, are likely to boost investor confidence in Celldex's pipeline, potentially driving the stock price up. The advancement to Phase 3 trials further supports this positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100